Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,158
Recruiting: 2,257
Ph III recruiting: 267
Growth YoY: +13.5%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,894)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06910072	Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）(UPGRADE-TNBC)	enrolling by invitation	Phase 2 / Phase 3	32	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Aug 18, 2026	clinicaltrials
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	enrolling by invitation	Phase 3	5,000	ExelixisINDUSTRY